Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs

A. Jakobovits, L. L. Green, M. C. Hardy, C. E. Maynard-Currie, H. Tsuda, D. M. Louie, M. J. Mendez, H. Abderrahim, M. Noguchi, D. H. Smith, Y. Zeng, N. E. David, H. Sasai, D. Garza, D. G. Brenner, J. F. Hales, R. P. McGuinness, D. J. Capon, S. Klapholz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Our paper describes the introduction of large fragments of both the human heavy and light chain Ig genes into the mouse germline to create a mouse strain capable of producing a broad repertoire of antigen-specific, fully human antibodies. The human immunoglobulin gene sequences were functional in the context of the mouse machinery for antibody recombination and expression, either in the presence or absence of functional endogenous genes. This was demonstrated by their ability to undergo diverse rearrangement, to be expressed at significant levels, and to exclude expression of mouse immunoglobulins irrespective of their copy number or site of integration. The decrease in susceptibility to influence by adjacent genomic sequences may reflect the greater size, variable gene content, or structural integrity of the human Ig YACs and/or the presence of unidentified but important regulatory elements needed for optimal expression of the human immunoglobulin genes and their correct regulation. Our results show that mouse B cells coexpressing human heavy and kappa chains, upon immunization, can produce antigen-specific, fully human antibodies. Furthermore, the human heavy and kappa chain YACs induced differentiation and maturation of the growth-arrested B-cell lineage in mice with inactivated endogenous Ig genes, leading to the production of a diverse repertoire of fully human antibodies at levels approaching those in normal serum. These results suggest the potential value of these mice as a source of fully human antibodies for human therapy. Furthermore, it is expected that such mice would lack immunological tolerance to and thus readily yield antibodies to human proteins, which may constitute an important class of targets for monoclonal antibody therapy. Our findings suggest that the introduction of even larger portions of the human heavy and light chain loci, which should be achievable with the ES cell-yeast spheroplast fusion technology described, will result in strains of mice ultimately capable of recapitulating the full antibody repertoire characteristic of the human humoral response to infection and immunization. The present and future mouse strains may prove to be valuable tools for studying the molecular mechanisms and regulatory sequences influencing the programmed assembly and expression of human antibodies in the normal immune response, as well as the abnormal response characteristic of autoimmune disease and other disorders. The strategy we have described for the introduction of large segments of the human genome into mice in conjunction with the inactivation of the corresponding mouse loci may also have broad applicability to the investigation of other complex or uncharacterized loci.

Original languageEnglish
Pages (from-to)525-535
Number of pages11
JournalAnnals of the New York Academy of Sciences
Volume764
Publication statusPublished - 1 Dec 1995
Externally publishedYes

Fingerprint

Genes
Light
Antigens
Antibodies
Immunization
Immunoglobulin Genes
Immunoglobulins
Cells
Mouse
Structural integrity
Yeast
Machinery
B-Lymphocytes
Fusion reactions
Spheroplasts
Monoclonal Antibodies
Cell Lineage
Human Genome
Genetic Recombination
Autoimmune Diseases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jakobovits, A., Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., ... Klapholz, S. (1995). Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Annals of the New York Academy of Sciences, 764, 525-535.

Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. / Jakobovits, A.; Green, L. L.; Hardy, M. C.; Maynard-Currie, C. E.; Tsuda, H.; Louie, D. M.; Mendez, M. J.; Abderrahim, H.; Noguchi, M.; Smith, D. H.; Zeng, Y.; David, N. E.; Sasai, H.; Garza, D.; Brenner, D. G.; Hales, J. F.; McGuinness, R. P.; Capon, D. J.; Klapholz, S.

In: Annals of the New York Academy of Sciences, Vol. 764, 01.12.1995, p. 525-535.

Research output: Contribution to journalArticle

Jakobovits, A, Green, LL, Hardy, MC, Maynard-Currie, CE, Tsuda, H, Louie, DM, Mendez, MJ, Abderrahim, H, Noguchi, M, Smith, DH, Zeng, Y, David, NE, Sasai, H, Garza, D, Brenner, DG, Hales, JF, McGuinness, RP, Capon, DJ & Klapholz, S 1995, 'Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs', Annals of the New York Academy of Sciences, vol. 764, pp. 525-535.
Jakobovits A, Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM et al. Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Annals of the New York Academy of Sciences. 1995 Dec 1;764:525-535.
Jakobovits, A. ; Green, L. L. ; Hardy, M. C. ; Maynard-Currie, C. E. ; Tsuda, H. ; Louie, D. M. ; Mendez, M. J. ; Abderrahim, H. ; Noguchi, M. ; Smith, D. H. ; Zeng, Y. ; David, N. E. ; Sasai, H. ; Garza, D. ; Brenner, D. G. ; Hales, J. F. ; McGuinness, R. P. ; Capon, D. J. ; Klapholz, S. / Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. In: Annals of the New York Academy of Sciences. 1995 ; Vol. 764. pp. 525-535.
@article{df21760257394337b57323a7577ce01d,
title = "Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs",
abstract = "Our paper describes the introduction of large fragments of both the human heavy and light chain Ig genes into the mouse germline to create a mouse strain capable of producing a broad repertoire of antigen-specific, fully human antibodies. The human immunoglobulin gene sequences were functional in the context of the mouse machinery for antibody recombination and expression, either in the presence or absence of functional endogenous genes. This was demonstrated by their ability to undergo diverse rearrangement, to be expressed at significant levels, and to exclude expression of mouse immunoglobulins irrespective of their copy number or site of integration. The decrease in susceptibility to influence by adjacent genomic sequences may reflect the greater size, variable gene content, or structural integrity of the human Ig YACs and/or the presence of unidentified but important regulatory elements needed for optimal expression of the human immunoglobulin genes and their correct regulation. Our results show that mouse B cells coexpressing human heavy and kappa chains, upon immunization, can produce antigen-specific, fully human antibodies. Furthermore, the human heavy and kappa chain YACs induced differentiation and maturation of the growth-arrested B-cell lineage in mice with inactivated endogenous Ig genes, leading to the production of a diverse repertoire of fully human antibodies at levels approaching those in normal serum. These results suggest the potential value of these mice as a source of fully human antibodies for human therapy. Furthermore, it is expected that such mice would lack immunological tolerance to and thus readily yield antibodies to human proteins, which may constitute an important class of targets for monoclonal antibody therapy. Our findings suggest that the introduction of even larger portions of the human heavy and light chain loci, which should be achievable with the ES cell-yeast spheroplast fusion technology described, will result in strains of mice ultimately capable of recapitulating the full antibody repertoire characteristic of the human humoral response to infection and immunization. The present and future mouse strains may prove to be valuable tools for studying the molecular mechanisms and regulatory sequences influencing the programmed assembly and expression of human antibodies in the normal immune response, as well as the abnormal response characteristic of autoimmune disease and other disorders. The strategy we have described for the introduction of large segments of the human genome into mice in conjunction with the inactivation of the corresponding mouse loci may also have broad applicability to the investigation of other complex or uncharacterized loci.",
author = "A. Jakobovits and Green, {L. L.} and Hardy, {M. C.} and Maynard-Currie, {C. E.} and H. Tsuda and Louie, {D. M.} and Mendez, {M. J.} and H. Abderrahim and M. Noguchi and Smith, {D. H.} and Y. Zeng and David, {N. E.} and H. Sasai and D. Garza and Brenner, {D. G.} and Hales, {J. F.} and McGuinness, {R. P.} and Capon, {D. J.} and S. Klapholz",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "764",
pages = "525--535",
journal = "Annals of The Lyceum of Natural History of New York",
issn = "0890-6564",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs

AU - Jakobovits, A.

AU - Green, L. L.

AU - Hardy, M. C.

AU - Maynard-Currie, C. E.

AU - Tsuda, H.

AU - Louie, D. M.

AU - Mendez, M. J.

AU - Abderrahim, H.

AU - Noguchi, M.

AU - Smith, D. H.

AU - Zeng, Y.

AU - David, N. E.

AU - Sasai, H.

AU - Garza, D.

AU - Brenner, D. G.

AU - Hales, J. F.

AU - McGuinness, R. P.

AU - Capon, D. J.

AU - Klapholz, S.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Our paper describes the introduction of large fragments of both the human heavy and light chain Ig genes into the mouse germline to create a mouse strain capable of producing a broad repertoire of antigen-specific, fully human antibodies. The human immunoglobulin gene sequences were functional in the context of the mouse machinery for antibody recombination and expression, either in the presence or absence of functional endogenous genes. This was demonstrated by their ability to undergo diverse rearrangement, to be expressed at significant levels, and to exclude expression of mouse immunoglobulins irrespective of their copy number or site of integration. The decrease in susceptibility to influence by adjacent genomic sequences may reflect the greater size, variable gene content, or structural integrity of the human Ig YACs and/or the presence of unidentified but important regulatory elements needed for optimal expression of the human immunoglobulin genes and their correct regulation. Our results show that mouse B cells coexpressing human heavy and kappa chains, upon immunization, can produce antigen-specific, fully human antibodies. Furthermore, the human heavy and kappa chain YACs induced differentiation and maturation of the growth-arrested B-cell lineage in mice with inactivated endogenous Ig genes, leading to the production of a diverse repertoire of fully human antibodies at levels approaching those in normal serum. These results suggest the potential value of these mice as a source of fully human antibodies for human therapy. Furthermore, it is expected that such mice would lack immunological tolerance to and thus readily yield antibodies to human proteins, which may constitute an important class of targets for monoclonal antibody therapy. Our findings suggest that the introduction of even larger portions of the human heavy and light chain loci, which should be achievable with the ES cell-yeast spheroplast fusion technology described, will result in strains of mice ultimately capable of recapitulating the full antibody repertoire characteristic of the human humoral response to infection and immunization. The present and future mouse strains may prove to be valuable tools for studying the molecular mechanisms and regulatory sequences influencing the programmed assembly and expression of human antibodies in the normal immune response, as well as the abnormal response characteristic of autoimmune disease and other disorders. The strategy we have described for the introduction of large segments of the human genome into mice in conjunction with the inactivation of the corresponding mouse loci may also have broad applicability to the investigation of other complex or uncharacterized loci.

AB - Our paper describes the introduction of large fragments of both the human heavy and light chain Ig genes into the mouse germline to create a mouse strain capable of producing a broad repertoire of antigen-specific, fully human antibodies. The human immunoglobulin gene sequences were functional in the context of the mouse machinery for antibody recombination and expression, either in the presence or absence of functional endogenous genes. This was demonstrated by their ability to undergo diverse rearrangement, to be expressed at significant levels, and to exclude expression of mouse immunoglobulins irrespective of their copy number or site of integration. The decrease in susceptibility to influence by adjacent genomic sequences may reflect the greater size, variable gene content, or structural integrity of the human Ig YACs and/or the presence of unidentified but important regulatory elements needed for optimal expression of the human immunoglobulin genes and their correct regulation. Our results show that mouse B cells coexpressing human heavy and kappa chains, upon immunization, can produce antigen-specific, fully human antibodies. Furthermore, the human heavy and kappa chain YACs induced differentiation and maturation of the growth-arrested B-cell lineage in mice with inactivated endogenous Ig genes, leading to the production of a diverse repertoire of fully human antibodies at levels approaching those in normal serum. These results suggest the potential value of these mice as a source of fully human antibodies for human therapy. Furthermore, it is expected that such mice would lack immunological tolerance to and thus readily yield antibodies to human proteins, which may constitute an important class of targets for monoclonal antibody therapy. Our findings suggest that the introduction of even larger portions of the human heavy and light chain loci, which should be achievable with the ES cell-yeast spheroplast fusion technology described, will result in strains of mice ultimately capable of recapitulating the full antibody repertoire characteristic of the human humoral response to infection and immunization. The present and future mouse strains may prove to be valuable tools for studying the molecular mechanisms and regulatory sequences influencing the programmed assembly and expression of human antibodies in the normal immune response, as well as the abnormal response characteristic of autoimmune disease and other disorders. The strategy we have described for the introduction of large segments of the human genome into mice in conjunction with the inactivation of the corresponding mouse loci may also have broad applicability to the investigation of other complex or uncharacterized loci.

UR - http://www.scopus.com/inward/record.url?scp=0029551923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029551923&partnerID=8YFLogxK

M3 - Article

C2 - 7486581

AN - SCOPUS:0029551923

VL - 764

SP - 525

EP - 535

JO - Annals of The Lyceum of Natural History of New York

JF - Annals of The Lyceum of Natural History of New York

SN - 0890-6564

ER -